Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 2Phase 1/2 1

Status

Unknown 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Leukemia, Myeloid, Acute 34Leukemia 26Lymphoma, Non-Hodgkin 23Lymphoma 22Precursor Cell Lymphoblastic Leukemia-Lymphoma 21Recurrence 19Leukemia, Lymphocytic, Chronic, B-Cell 19Myelodysplastic Syndromes 18Hematologic Neoplasms 18Melanoma 16Neoplasm Metastasis 15Lymphoma, B-Cell 14Multiple Myeloma 12Pancreatic Neoplasms 11Hodgkin Disease 11Stomach Neoplasms 10Ovarian Neoplasms 10Lymphoma, Large B-Cell, Diffuse 10Breast Neoplasms 9Leukemia, Myelogenous, Chronic, BCR-ABL Positive 8Lymphoma, Mantle-Cell 7Lymphoma, Follicular 7Uterine Cervical Neoplasms 6Neoplasms 6Carcinoma, Non-Small-Cell Lung 6Triple Negative Breast Neoplasms 5Neoplasms, Plasma Cell 5Kidney Neoplasms 5Burkitt Lymphoma 5Myeloproliferative Disorders 4

Interventions

pembrolizumab 2Cyclophosphamide 2siltuximab 1ruxolitinib 1ricolinostat 1repotrectinib 1pralsetinib 1ponatinib 1pomalidomide 1pamiparib 1fludarabine 1ficlatuzumab 1enzalutamide 1blinatumomab 1Taxes 1Radiation 1Pemetrexed 1Paclitaxel 1Gefitinib 1Drug Therapy 1Dexamethasone 1Cisplatin 1CPI-0610 1Bortezomib 1Biopsy 1Bevacizumab 1Bendamustine Hydrochloride 1ARQ531 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Neoplasms by Histologic Type × fludarabine × Clear all
NCT05155215 2021-12-13

Study to Evaluate the Safety and Efficacy of IM19 CAR-T Cells in Patients With Relapsed and Refractory (R/R) Mantle Cell Lymphoma

Beijing Immunochina Medical Science & Technology Co., Ltd.

Phase 1/2 Unknown
68 enrolled
Lymphoid

Lymphoma, Lymphoproliferative Disorders, Neoplasms, Neoplasms by Histologic Type, Lymphoma, Mantle-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡